GlassScriptPhysician profile
Russell M Eldridge
NPI 1548261423
$345.60
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $118.74 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $95.78 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.08 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.32 | 2019 | |
| Seagen INC. | $15.97 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.94 | 2019 | |
| Clovis Oncology, INC. | $15.43 | 2019 | |
| Genentech USA, INC. | $12.53 | 2019 | |
| Exelixis INC. | $12.52 | 2019 | |
| Celgene Corporation | $12.29 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Eldridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.